NEW YORK, NY, USA (Press Release) - May 29, 2009
Your session will expire in 8 hours requiring you to log in each day to view content.
Browse Categories
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Your session will expire in 8 hours requiring you to log in each day to view content.